• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complement C5 inhibition in patients with COVID-19 - a promising target?

作者信息

Peffault de Latour Regis, Bergeron Anne, Lengline Etienne, Dupont Thibault, Marchal Armance, Galicier Lionel, de Castro Nathalie, Bondeelle Louise, Darmon Michael, Dupin Clairelyne, Dumas Guillaume, Leguen Pierre, Madelaine Isabelle, Chevret Sylvie, Molina Jean-Michel, Azoulay Elie, Fremeaux-Bacchi Veronique

机构信息

Saint Louis Hospital.

Saint-Louis Hospital.

出版信息

Haematologica. 2020 Dec 1;105(12):2847-2850. doi: 10.3324/haematol.2020.260117.

DOI:10.3324/haematol.2020.260117
PMID:33256385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7716359/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf69/7716359/d1cdb50983f3/1052847.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf69/7716359/d1cdb50983f3/1052847.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf69/7716359/d1cdb50983f3/1052847.fig1.jpg

相似文献

1
Complement C5 inhibition in patients with COVID-19 - a promising target?新冠病毒肺炎患者中补体C5抑制——一个有前景的靶点？
Haematologica. 2020 Dec 1;105(12):2847-2850. doi: 10.3324/haematol.2020.260117.
2
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.补体 C3 与 C5 抑制在重症 COVID-19 中的作用：早期临床发现揭示了不同的生物学疗效。
Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19.
3
COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.接受抗补体治疗的患者感染新型冠状病毒肺炎：利兹国家阵发性夜间血红蛋白尿症服务经验
Br J Haematol. 2020 Oct;191(1):e1-e4. doi: 10.1111/bjh.17097. Epub 2020 Sep 18.
4
Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).用新型补体C5抑制剂覆盖素（诺马科潘）成功治疗对依库珠单抗无反应的阵发性睡眠性血红蛋白尿症患者。
Br J Haematol. 2020 Jan;188(2):334-337. doi: 10.1111/bjh.16305. Epub 2019 Dec 16.
5
[Complement-Mediated Mechanism and Complement Inhibitors in Guillain-Barré Syndrome].[格林-巴利综合征中的补体介导机制与补体抑制剂]
Brain Nerve. 2019 Jun;71(6):581-587. doi: 10.11477/mf.1416201319.
6
Drugs that inhibit complement.抑制补体的药物。
Transfus Apher Sci. 2012 Feb;46(1):87-92. doi: 10.1016/j.transci.2011.11.012. Epub 2011 Dec 13.
7
COVID-19 Updates: Monoclonal Antibodies for COVID-19.新冠疫情最新消息：用于治疗新冠的单克隆抗体
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.
8
Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation.抗C5作为亲属活体肾移植中不典型溶血尿毒综合征的预防性治疗。
Transplantation. 2013 Aug 27;96(4):e26-9. doi: 10.1097/TP.0b013e31829d388d.
9
C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.C1酯酶抑制：针对新冠病毒中的多个系统
J Clin Immunol. 2021 May;41(4):729-732. doi: 10.1007/s10875-021-00972-1. Epub 2021 Jan 21.
10
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.3例接受靶向C5补体的治疗性单克隆抗体治疗血液系统疾病的COVID-19患者的临床病程较轻。
Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.

引用本文的文献

1
Enhanced complement activation and MAC formation accelerates severe COVID-19.补体激活增强和膜攻击复合物形成加速重症新型冠状病毒肺炎。
Cell Mol Life Sci. 2024 Sep 16;81(1):405. doi: 10.1007/s00018-024-05430-w.
2
Complement system activation: bridging physiology, pathophysiology, and therapy.补体系统激活：连接生理学、病理生理学和治疗学。
Intensive Care Med. 2024 Nov;50(11):1791-1803. doi: 10.1007/s00134-024-07611-4. Epub 2024 Sep 10.
3
Emerging role of complement in COVID-19 and other respiratory virus diseases.补体系统在 COVID-19 和其他呼吸道病毒疾病中的新作用。
Cell Mol Life Sci. 2024 Feb 18;81(1):94. doi: 10.1007/s00018-024-05157-8.
4
COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study.COVID-19 疫苗接种可预防更严重的病情，在奥密克戎大流行期间，补体抑制剂治疗可减少 PNH 患者的溶血恶化：一项单中心研究。
Ann Med. 2023;55(2):2274510. doi: 10.1080/07853890.2023.2274510. Epub 2024 Jan 1.
5
Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review.新型冠状病毒肺炎相关肺血栓形成机制：一篇叙述性综述
Biomedicines. 2023 Mar 16;11(3):929. doi: 10.3390/biomedicines11030929.
6
Levels of Complement Components in Children With Acute COVID-19 or Multisystem Inflammatory Syndrome.急性 COVID-19 或多系统炎症综合征患儿补体成分水平。
JAMA Netw Open. 2023 Mar 1;6(3):e231713. doi: 10.1001/jamanetworkopen.2023.1713.
7
Factor H autoantibodies contribute to complement dysregulation in multisystem inflammatory syndrome in children (MIS-C).补体因子H自身抗体导致儿童多系统炎症综合征（MIS-C）中的补体失调。
Am J Hematol. 2023 May;98(5):E98-E101. doi: 10.1002/ajh.26868. Epub 2023 Feb 13.
8
COVID-19 vaccination and Atypical hemolytic uremic syndrome.COVID-19 疫苗接种与非典型溶血尿毒综合征。
Front Immunol. 2022 Dec 1;13:1056153. doi: 10.3389/fimmu.2022.1056153. eCollection 2022.
9
Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.补体激活可预测 COVID-19 的不良结局：来自意大利北部患者的经验。
Autoimmun Rev. 2023 Jan;22(1):103232. doi: 10.1016/j.autrev.2022.103232. Epub 2022 Nov 19.
10
Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.补体介导的微血管损伤和血栓形成在重症 COVID-19 发病机制中的作用：综述
World J Exp Med. 2022 Jul 20;12(4):53-67. doi: 10.5493/wjem.v12.i4.53.